Drug Development.

Area of Science:

• Neurology
• Pharmacology

Background:

• Lecanemab, a monoclonal antibody, targets amyloid-beta (Aβ) protofibrils and plaques.
• It has demonstrated efficacy in slowing clinical decline in early Alzheimer's disease (AD).

Purpose of the Study:

• To present real-world clinical experience with lecanemab in early AD patients.
• To evaluate the safety and tolerability of lecanemab in a clinical setting.

Main Methods:

• Retrospective case series of 35 early AD patients treated with lecanemab.
• Data included demographics, clinical history, treatment exposure, MMSE, MoCA, and safety assessments.
• Clinician perspectives and patient survey feedback were collected.

Main Results:

• Improved mean MMSE and MoCA scores at 6 and 12 months.
• Favorable safety profile with manageable adverse events like ARIA and infusion-site reactions.
• 80% patient satisfaction reported, with perceived stabilization or slowing of disease progression.

Conclusions:

• Real-world evidence supports lecanemab's safety and tolerability in early AD.
• Findings align with clinical trials demonstrating lecanemab's ability to slow disease progression.
• Further longitudinal studies are needed to assess long-term outcomes.